TECENTRIQ Proposed Mechanism of Action

PD-L1 can contribute to immune deactivation in the tumor microenvironment 1

  • PD-L1 may be expressed on tumor cells and tumor-infiltrating immune cells
  • Binding of the ligand PD-L1 to its inhibitory receptors PD-1 and B7.1 on T cells can suppress cytotoxic T-cell activity

TECENTRIQ targets the ligand PD-L1 to restore antitumor T-cell cell activity 1

  • Restoring T-cell activity could affect both tumor and normal cells

Distinct features of TECENTRIQ

  • DIRECT: TECENTRIQ binds to the ligand PD-L1 on tumor cells and immune cells
  • COMPLETE: dual blockade of PD-L1 binding to its inhibitory receptors PD-1 and B7.1

About TECENTRIQ:
TECENTRIQ is the first FDA-approved, Fc-engineered, humanized anti-PDL1 antibody

PD-L1=programmed death-ligand 1.